The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index; 22 of the 45 sources its claims cite were checked for support.
Efficacy and safety of esketamine for “treatment resistant depression”: registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials
Open accessAbstract
BACKGROUND: In 2019, the FDA and EMA approved intranasal esketamine for treatment-resistant depression (TRD). The current study re-evaluated its efficacy and safety. METHODS: This registered report presents a systematic review and individual patient data (IPD) meta-analysis of double-blind, randomised, placebo-controlled trials (RCTs) assessing intranasal esketamine for TRD. Two reviewers independently screened studies from multiple databases and obtained IPD via the Yale Open Data Access Project. Two independent researchers selected studies and assessed risk of bias. The primary outcome was the Montgomery-Åsberg Depression Rating Scale (MADRS) score at ≥ 4 weeks in initiation trials, benchmarked against the 6.5-point clinical significance threshold used in the design of pivotal trials. Evidence certainty was rated using GRADE. Secondary outcomes included additional efficacy and safety endpoints. A two-step IPD meta-analysis was conducted, with separate analyses by trial phase (initiation vs. continuation) and treatment type (combination vs. monotherapy). A one-stage meta-analysis explored moderators (e.g. age and resistance level). RESULTS: We re-analysed IPD from 7 RCTs including 1505 patients. In five initiation trials of esketamine plus an antidepressant, esketamine reduced MADRS scores at 4 weeks (mean difference (MD) = - 2.94, 95% CI [- 5.39 to - 0.48]; GRADE: moderate certainty). A continuation trial showed reduced relapse risk (HR = 0.38 [0.26-0.57]), though FDA concerns about one centre could not be addressed due to data privacy restrictions. A monotherapy trial (aggregate data only) showed a larger effect (MD = - 6.32 [- 8.62 to - 4.03]), but there were concerns over selection bias and unblinding. Esketamine increased sedation (RR = 3.70 [2.02-6.78]), dissociation (RR = 2.36 [2.10-2.65]), and adverse events (IRR = 3.91 [2.37-6.45]), with no increase in serious adverse events (IRR = 1.35 [0.54-3.40]). No treatment effect moderation was found by age or resistance level, with most patients displaying low-stage TRD. CONCLUSIONS: Based on the IPD used for approval, esketamine in combination with an antidepressant showed an advantage over placebo that was statistically significant but small. The clinical relevance of this benefit is unclear, particularly given the risks of adverse events. STUDY REGISTRATION: PROSPERO: CRD42021290721.
Overview
CoChat Summary
TL;DR
In this individual patient data meta-analysis of 7 placebo-controlled esketamine trials including 1505 patients, esketamine plus an antidepressant produced a statistically significant but small MADRS reduction at 4 weeks (MD −2.94) that fell below the trials’ prespecified 6.5-point clinical significance threshold. Esketamine increased adverse events, dissociation, and sedation without increasing serious adverse events, and no efficacy moderation by age or resistance stage was found.
Key findings
- In five initiation trials of esketamine plus an antidepressant, esketamine reduced MADRS scores at ≥4 weeks versus placebo (MD = −2.94, 95% CI [−5.39 to −0.48]; GRADE moderate certainty), but the entire confidence interval failed to meet the prespecified −6.5-point threshold; the effect corresponded to SMD −0.25 (95% CI −0.45 to −0.06).
- In the continuation trial, esketamine reduced relapse risk (HR = 0.38 [0.26–0.57]), but FDA concerns about one centre could not be addressed due to data privacy restrictions; excluding all Polish centres reduced the primary remission effect and made it non-significant.
- A monotherapy trial using aggregate data only showed a larger effect (MD = −6.32 [−8.62 to −4.03]), but the paper reports concerns over selection bias and functional unblinding.
- Esketamine increased sedation (RR = 3.70 [2.02–6.78]), dissociation (RR = 2.36 [2.10–2.65]), and adverse events (IRR = 3.91 [2.37–6.45]), with no increase in serious adverse events (IRR = 1.35 [0.54–3.40]); no treatment effect moderation was found by age or resistance level, and most patients had low-stage TRD.
Methods
- Systematic review and individual patient data meta-analysis of double-blind, randomised, placebo-controlled trials of intranasal esketamine for treatment-resistant depression; registered on PROSPERO (CRD42021290721), reported per PRISMA and PRISMA-IPD, with IPD obtained via the Yale Open Data Access Project.
- Two-step IPD meta-analysis conducted separately by trial phase (initiation vs. continuation) and treatment type (combination vs. monotherapy); primary outcome was MADRS score at ≥4 weeks, benchmarked against the 6.5-point clinical significance threshold used in pivotal trials; one-stage meta-analysis explored moderators including age and resistance level; GRADE assessed certainty.
- Data included 7 RCTs with 1505 randomised participants: six initiation studies (one 1-week, five 4-week) and one continuation study; one monotherapy RCT (476 participants) was analysed separately from aggregate data because IPD were unavailable.
Limitations
- The paper states that centre information was missing from the IPD due to anonymisation, so the FDA concern about a specific centre in Poland could not be directly investigated; the country-based analysis was considered weak and exploratory.
- The paper states that two initiation trials showed unexpected data patterns before and after interim analysis, indicating potential bias, and that functional unblinding was likely because no formal assessment of unblinding was conducted in pivotal RCTs.
- The paper states that prior ECT use was not systematically assessed, reconstructing several variables and resistance stage introduced methodological variability, few patients had high resistance limiting subgroup power, and too few studies were available for a funnel plot.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
16 Valid · 0 Not valid · 19 Not checked · 70 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In one of those (NCT02417064 [9]), statistical significance should not have been tested for the 56 mg treatment group due to the hierarchical analysis and the absence of a significant difference in the 84 mg group tested first.”
§ Efficacy and safety of esketamine for “treatment resistant depression”: registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials > Results > IPD integrity and re-analyses
What the sources say
- Partly supportedcites [9] Fedgchin M, Trivedi M, Daly EJ, Melkote R, Lane R, Lim P, et al. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J Neuropsychopharmacol. 2019;22(10):616–30. sourceExperimental — accuracy not yet measured
Statistical Methods says the 56 mg group could be formally tested only if the 84 mg group was significant. Study Results reports that the 84 mg comparison was not significant, so the 56 mg group could not be formally evaluated under the predefined sequence. The claim omits an important distinction: the authors did perform and report a nominal statistical test for the 56 mg group. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Moreover, the approval of quetiapine for TRD was based on an even more lenient definition of resistance, requiring failure of only one prior antidepressant [50].”
§ Efficacy and safety of esketamine for “treatment resistant depression”: registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials > Discussion > Implications
What the sources say
- Supportedcites [50] Saelens J, Gramser A, Watzal V, Zarate CA Jr, Lanzenberger R, Kraus C. Relative effectiveness of antidepressant treatments in treatment-resistant depression: a systematic review and network meta-analysis of randomized controlled trials. Neuropsychopharmacology. 2025;50(6):913–9. source
The Discussion states that FDA approval of quetiapine was based on studies defining treatment resistance as lack of response to a single antidepressant. It contrasts that definition with the paper’s more stringent two-treatment criterion. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“After our pieces drew attention to this issue, the sponsor reported a sensitivity analysis [14]: the p-value changed from highly significant to “barely significant” [8].”
§ Efficacy and safety of esketamine for “treatment resistant depression”: registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials > Background
What the sources say
- Supportedcites [14] Singh JB, Daly EJ, Mathews M, Fedgchin M, Popova V, Hough D, et al. Approval of esketamine for treatment-resistant depression. Lancet Psychiatry. 2020;7(3):232–5. source
The ‘Approval of esketamine for treatment-resistant depression’ section reports a sensitivity analysis excluding the questioned site and gives a log-rank p-value of 0.048. That supports the sponsor’s report of a barely significant sensitivity result; the citing authors’ account of what prompted it is their own framing. (LLM, conf=0.92)
- Supportedcites [8] Turner EH. Approval of esketamine for treatment-resistant depression-author’s reply. Lancet Psychiatry. 2020;7(3):236. source
In the Author's reply, Turner reports that after the sponsor excluded the outlier site, the p-value increased from 0.003 to a “barely significant” 0.048. This directly supports the change attributed to this source; the sentence cites a different source for the sponsor's sensitivity analysis. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“More concerningly, the FDA described in its assessment some possible data integrity issues for two trials [5].”
§ Efficacy and safety of esketamine for “treatment resistant depression”: registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials > Background
What the sources say
- Partly supportedcites [5] Cristea IA, Naudet F. US food and drug administration approval of esketamine and brexanolone. Lancet Psychiatry. 2019;6(12):975–7. sourceExperimental — accuracy not yet measured
In the main text (page unavailable), the paper says an FDA reviewer described data integrity issues for one trial. It does not support the citing sentence’s count of two trials. (LLM, conf=0.91)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“two [9, 10] out of the 3 pivotal initiation RCTs [9–11] failed to demonstrate that esketamine was superior to placebo [5]”
§ Efficacy and safety of esketamine for “treatment resistant depression”: registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials > Background
What the sources say
- Supportedcites [9] Fedgchin M, Trivedi M, Daly EJ, Melkote R, Lane R, Lim P, et al. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J Neuropsychopharmacol. 2019;22(10):616–30. source
The Discussion reports that this trial did not achieve statistical significance for esketamine 84 mg plus an antidepressant versus placebo nasal spray plus an antidepressant. This source supports its role as one of the two cited trials that failed to demonstrate superiority; it does not itself establish the two-of-three count. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [10] Ochs-Ross R, Daly EJ, Zhang Y, Lane R, Lim P, Morrison RL, et al. Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-TRANSFORM-3. Am J Geriatr Psychiatry. 2020;28(2):121–41. source
- Supportedcites [5] Cristea IA, Naudet F. US food and drug administration approval of esketamine and brexanolone. Lancet Psychiatry. 2019;6(12):975–7. source
The paper’s discussion of the pivotal trials states that, for esketamine, one short-term trial showed a significant benefit over placebo while two others found no difference. This supports the claim about two of the three initiation trials. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
67 more claims · 3 with their cited sources checked
Create a free account to see all 105 claims and to verify the 2 references still open.
- Probably not a substantial claim. 15
- It may state two separate claims as one. 25
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent secondary evidence has likewise concluded that intranasal esketamine improves depressive symptoms and response outcomes in TRD while increasing acute adverse effects such as dizziness and nausea, which is consistent with our safety synthesis (26–28)”
From Intranasal esketamine plus oral antidepressant for treatment-resistant depression: acute induction and maintenance relapse-prevention outcomes in a systematic review and meta-analysis (2026) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Multiple evidence syntheses of esketamine have been published, generally indicating statistically significant symptom improvement versus placebo but raising questions about clinical magnitude, heterogeneity across trials and populations, and trade-offs in adverse events (26–28).”
The cited source says what the claim attributes to it.
In the citing paper
“Nevertheless, uncertainty persists regarding (i) consistency of short-term efficacy across induction trials (including older adults), (ii) durability of benefit during maintenance and relapse prevention, (iii) comparative impact on functional outcomes, and (iv) the frequency and clinical relevance of key adverse events and discontinuations.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Efficacy and safety of esketamine for “treatment resistant depression”: registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials > Methods > Participants, interventions, comparators, outcomes and study design (PICOS)
“TRD refers to a depressive episode with inadequate response to at least two antidepressant trials of adequate doses and duration.”
§ Efficacy and safety of esketamine for “treatment resistant depression”: registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials > Methods > Participants, interventions, comparators, outcomes and study design (PICOS)
“The IPD analysis was then restricted to participants/patients with TRD within the included studies (i.e. have failed > 2 adequate antidepressant trials).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Efficacy and safety of esketamine for “treatment resistant depression”: registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials > Results > Reporting bias
“In total, we identified one potentially relevant study without IPD and no aggregated data for analysis.”
§ Efficacy and safety of esketamine for “treatment resistant depression”: registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials > Results > Results of individual studies and results of syntheses
“Based on the aggregated data in one monotherapy trial, the statistical superiority of esketamine was evidenced for the primary outcome (Fig. 5), specifically the MADRS score assessed after at 4 weeks in the unique available initiation trial in monotherapy (MD = − 6.32 points, 95% CI [− 8.62; − 4.03]).”
Citations
Cites
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Page, M. J., Moher, D., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n160 · Cited by 13,262
Sterne, J. A. C., Sutton, A. J., Ioannidis, J. P. A., Terrin, N., Jones, D. R., Lau, J., Carpenter, J., Rucker, G., Harbord, R. M., Schmid, C. H., et al. (2011) · BMJ · doi:10.1136/bmj.d4002 · Cited by 7,709 · cited 1×
“There were too few studies to generate a funnel plot [43].”
Outlier and influence diagnostics for meta-analysis
Viechtbauer, W., & Cheung, M. W.-L. (2010) · Research Synthesis Methods · doi:10.1002/jrsm.11 · Cited by 2,949 · cited 1×
“For each RCT, we planned to explore a center effect by performing sensitivity analyses removing a center at a time (leave-one-out analysis [32]).”
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904 · cited 4×
“The randomised controlled initiation trials (RCTs) barely demonstrate short-term benefits and did not investigate long-term efficacy of esketamine in that two [9, 10] out of the 3 pivotal initiation RCTs [9–11] failed to demonstrate that esketamine was superior to placebo [5].”
InfluentialDaly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., Lane, R., Lim, P., Duca, A. R., Hough, D., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1189 · Cited by 795 · cited 4×
“In the continuation trial (NCT02493868 [12]), the primary outcome of remission remained consistent except when data from all Polish centers were excluded; in this case, the effect size decreased and the analysis was not statistically significant.”
Influential(1997) · PubMed · Cited by 727
Daly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3739 · Cited by 718
Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz039 · Cited by 606 · cited 6×
“Among these, six were initiation studies (1 with a 1-week duration [40], five with a 4-week duration [9–11, 41, 42] and one was a continuation study [12].”
Influential
Research works printed but not linked: 2
- Lan CH, Wei JC. Esketamine nasal spray versus quetiapine for resistant depression. N Engl J Med. 2024;390(1):93–4. · DOI · Paper page
- Pharmacoeconomic report: esketamine hydrochloride (Spravato): (Janssen Inc.): indication: major depressive disorder in adults. Ontario, Canada; 2021. https://www.ncbi.nlm.nih.gov/books/NBK572204/.
Cited by
Xie, J., Pu, C., & Sun, M. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1774549 · Cited by 1
An, J., Li, X., Li, Z., Wang, J., & Pan, Y. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04417-y · Cited by 4
“…depression (TRD) studies, inclusion requires non-response to at least two oral antidepressants of different mechanisms in the current episode, as assessed using standardized tools such as the Massachusetts General Hospital Antidepres-sant Treatment Response Questionnaire (MGH-ATRQ) [95, 98].”
InfluentialGómez-Juanes, R., Lázaro, G. M., Castro, A., Navarra‐Ventura, G., Quetglas, J. A. M., Marset, A. B., Monasterio, J. V. D. W., Trullols, J. A. G., Roca, M., Gili, M., et al. (2026) · The European Journal of Psychiatry · doi:10.1016/j.ejpsy.2026.100349 · Cited by 1
“Nevertheless, the magnitude of this benefit and its clinical relevance is a subject of ongoing debate, particularly for patients with extensive prior treatment failures 19,23 .”
InfluentialTHE IMPACT OF INTRANASAL ESKETAMINE ON TREATMENT-RESISTANT DEPRESSION: A SYSTEMATIC REVIEW
Kotlarski, W., Kotlarska, K. M., Mainka, T. S., & Sergejuk, E. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5523
Navigating the Depths of Depression: A Review of Genetic-Guided Treatment Approaches
Voiță, N. C., Pîrvu, C. A., Voiţă-Mekereş, F., Buleu, F. N., Motofelea, A. C., Buleu, T., & Pop, G. N. (2026) · Applied Sciences · doi:10.3390/app16083981
Metadata
- Authors
- Naudet, F., Pellen, C., Fodor, L. A., Gastaldon, C., Barbui, C., Turner, E. H., Le Pabic, E., & Cristea, I. A.
- Affiliations
- Inserm (FR)
- Babeș-Bolyai University (RO)
- University of Verona (IT)
- Oregon Health & Science University (US)
- University of Padua (IT)
- Corresponding author
- Naudet, Florian
- ORCID
- Venue
- BMC Medicine
- Published
- 2025-11-28
- Volume
- 23
- Issue
- 1
- Pages
- 677-677
- ISSN
- 1741-7015 (ISSN-L)
- PMC
- PMC12690855
- OpenAlex
- W4416769789
- Semantic Scholar
- 6c51c4708efd28807f1ea88aab1092ca795ecbb2
- Cited by
- 6
- References
- 37
- Citations by year
- 2026: 6
- FWCI
- 0.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor, 11 d)
- Locations
- BMC Medicine (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- HAL (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- direction de l’hospitalisation et de l’offre de soins (ESK-T-Dep)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- esketamine, treatment-resistant depression, intranasal administration, antidepressant monotherapy, combination therapy, relapse prevention, sedation, dissociation, adverse events, treatment efficacy, risk of bias, age and treatment response, resistance levels
- MeSH terms
- Pre-Registration Publication, Administration, Intranasal, Antidepressive Agents, Double-Blind Method, Humans, Ketamine, Randomized Controlled Trials as Topic, Treatment Outcome, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of esketamine for “treatment resistant depression”: registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials. https://app.cochat.ai/papers/10.1186/s12916-025-04435-x
- The paper
- Naudet, F., Pellen, C., Fodor, L. A., Gastaldon, C., Barbui, C., Turner, E. H., Le Pabic, E., & Cristea, I. A. (2025). Efficacy and safety of esketamine for “treatment resistant depression”: registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials. BMC Medicine. https://doi.org/10.1186/s12916-025-04435-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.